Cost-Effectiveness Analysis of Molecular Screening to Identify Lynch Syndrome in the Patients with Colorectal Cancer

Background: Identifying Lynch syndrome (LS) in patients with colorectal cancer (CRC) and monitoring their relatives can increase the life expectancy of these patients. Objectives: The aim this study was to analyze cost-effectiveness 5 molecular testing strategies screen LS among newly diagnosed CRC conduct preventive surveillance first-degree relatives. Methods: A decision tree model designed identify number mutations related costs Five were modeled, i.e., Amsterdam II criteria, microsatellite instability (MSI) testing, immunohistochemistry (IHC), next-generation sequencing (NGS). Markov also used estimate long-term outcome (including colonoscopy taking aspirin) those who carried LS. Results: All cost-effective compared no condition. 2 most strategy (IHC followed by NGS testing) 4 (MSI testing), ICER 4,604$ 4,748$ per quality-adjusted year (QALY), respectively. Based on one-way sensitivity analysis IHC sensitivity, Cost colonoscopy, MSI families inherited had effect results. Conclusions: findings suggested that from an Iranian health care system perspective, could be regarded as other strategies. These results useful offering